Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...

Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both ...

BRIDGEWATER, NJ, USA I March 14, 2025 I Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

While Deep Research was developed broadly for intensive knowledge work, Sanofi stands to benefit from its ability to capture and synthesize the latest findings in medicine and clinical research.

Sanofi plans to begin shipping flu vaccines ... Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

relief medicine Buscopan (hyoscine butylbromide), among others. Sales in the business totalled €5.6bn ($5.8bn) in 2023, accounting for 11% of Sanofi’s total business. Sanofi also claims Opella ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...